Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
-2.46 (-2.39%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 95.08 - 100.48
52 week 87.50 - 139.79
Open 98.00
Vol / Avg. 751,438.00/257,072.00
Mkt cap 2.05B
P/E     -
Div/yield     -
EPS -0.14
Shares 20.90M
Beta 1.38
Inst. own 119%
Feb 8, 2017
Q4 2016 Ligand Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -8.18% -2.17%
Operating margin 50.69% 40.27%
EBITD margin - 50.99%
Return on average assets -2.08% -0.43%
Return on average equity -3.54% -0.78%
Employees 21 -
CDP Score - -


3911 Sorrento Valley Blvd Ste 110
SAN DIEGO, CA 92121-1402
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Matthew W. Foehr President, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Matthew E. Korenberg Chief Financial Officer, Principal Accounting Officer, Vice President - Finance
Age: 41
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 47
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 55
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 44
Bio & Compensation  - Reuters
Stephen L. Sabba M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters